BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics develops RAS-targeting small molecules for KRAS-driven cancers.
SCHEDULE 13G/ANov 13Latest SEC filing
Nov 9Latest story
BridgeBio Oncology Therapeutics develops RAS-targeting small molecules for KRAS-driven cancers.